KR890008160A - 약학적 뉴클레오시드 - Google Patents

약학적 뉴클레오시드 Download PDF

Info

Publication number
KR890008160A
KR890008160A KR1019880014472A KR880014472A KR890008160A KR 890008160 A KR890008160 A KR 890008160A KR 1019880014472 A KR1019880014472 A KR 1019880014472A KR 880014472 A KR880014472 A KR 880014472A KR 890008160 A KR890008160 A KR 890008160A
Authority
KR
South Korea
Prior art keywords
formula
compound
pharmaceutically acceptable
purine
dideoxy
Prior art date
Application number
KR1019880014472A
Other languages
English (en)
Inventor
루이지 번즈 샬렌
메리 델루지 수잔
월터 코스잘카 죠지
안토니 크레니트스키 토마스
반 투틀 요엘
Original Assignee
엠.피.잭슨
더 웰컴 파운데이숀 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엠.피.잭슨, 더 웰컴 파운데이숀 리미티드 filed Critical 엠.피.잭슨
Publication of KR890008160A publication Critical patent/KR890008160A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

내용 없음

Description

약학적 뉴클레오시드
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (12)

  1. 바이러스 감염증의 치료 또는 예방에 유용한 하기식(I)의 3'-플루오로-2',3'-디데옥시뉴클레오시드 화합물 또는 이의 약학적 허용 유도체.
    상기식에서, B는 다음의 식으로 나타난다 :
    여기서 R1은 수소, 염소 또는 요오드원자이고, R2는 수소원자 또는 아미노기이고, R3는 C3-6시클로알킬 아미노, C1-6직쇄 또는 측쇄의 알콕시, C3-7시클로 알콕시 또는 질소원자를 통해 퓨린잔기에 결합되어 있는 5- 또는 6-원소의 헤테로 사이클릭 링이다.
  2. 제1항에 있어서, 인간이 리트로바이러스 감염증의 치료 또는 예방에 유용한 상기식(I)의 화합물 또는 이의 약학적 허용 유도체.
  3. 제1항에 있어서, 인간 면역 결핍 바이러스(HIV)감염증의 치료 또는 예방에 유용한 상기 식(I)의 화합물 또는 이의 염.
  4. 전항중 어느 한 항에 있어서, R3는 시클로프로필 아미노, 메톡시, 시클로펜톡시 또는 피페리디닐기를 나타내는 것을 특징으로하는 상기식(I)의 화합물 또는 이의 약학적 허용 유도체.
  5. 제1항 내지 제3항중 어느 한 항에 있어서, 다음으로 구성된 것으로 부터 선택되는 것을 특징으로 하는 화합물, 2',3'-디데옥시-3'-플루오로유리딘, 5-요오도-1-(2,3-디데옥시-3-플루오로-β-D-에리트로-펜토푸라노실)우라실, 5-클로로-1-(2,3-디데옥시-3-플루오로-β-D-에리트로-펜토푸라노실)우라실, 6-시클로프로필아미노-9-(β-D-2,3-디옥시-3-플루오로리보푸라노실-9H-퓨린, 2-아미노-6-메톡시-9-(β-D-2,3-디데옥시-3-플루오로 리보푸라노실)-9H-퓨린, 6-시클로펜톡시-9-(β-D-2,3-디데옥시-3-플루오로리보푸라노실)-9H-퓨린, 6-이소프로폭시-9-(β-D-2,3-디데옥시-3-플루오로리보푸라노실)-9H-푸린, 6-피페리디닐-9-(β-D-2,3-디데옥시-3-플루오로리보푸라노실)-9H-퓨린.
  6. 바이러스 감염증을 치료 또는 예방하는 의약제조에 사용되는 제1항에 정의된 상기식(I)의 화합물 또는 이의 약학적 허용유도체의 용도.
  7. 인간 ＆ 리트로바이어스 감염증을 치료 또는 예방하는 의약제조에 사용되는 제1항에 정의된 상기식(I)의 화합물 또는 이의 약학적 허용 유도체의 용도.
  8. 인간 면역 결핍 바이러스(HIV)감염증을 치료하기 위한 의약제조에 사용되는 제1항에 정의된 상기식(I)의 화합물 또는 이의 용도.
  9. 하기식(I)의 3'-플루오로-2',3'-디데옥시 뉴클레오시드 화합물 또는 이의 약학적 허용 유도체.
    상기식에서 B는 제1항에서 정의한 식(B)의 기를 나타낸다.
  10. 제9항에 있어서, 다음으로부터 선택된 것을 특징으로 하는 화합물, 6-시클로프로필아미노-9-(β-D-2,3-디데옥시-3-플루오로리보 푸라노실)9H-퓨린, 2-아미노-6-메톡시-9-(β-D-2,3-디데옥시-3-플루오로리보 푸라노실)-9H-퓨린, 6-시클로펜톡시-9-(β-D-2,3-디데옥시-3-플루오로리보 푸라노실)-9H-퓨린, 6-이소프로폭시-9-(β-D-2,3-디데옥시-3-플루오로리보 푸라노실)-9H-퓨린, 6-피페리디닐-9-(β-D-2,3-디데옥시-3-플루오로리보 푸라노실)-9H-퓨린.
  11. 제9항에서 정의된 적어도 하나의 상기식(I)의 화합물, 또는 이의 약학적 허용유도체 및 이의 약학적 허용담체등을 함유하는 약학적 조성물.
  12. 다음 단계로 구성되어 제9항에서 정의된 화합물 또는 이의 약학적 허용 유도체를 제조하는 방법, (A) 전구체기를 상응하는 바람직한 기로 전환시키는 조건하에 또는 이러한 전환을 돕는 반응제와 하기식(II)의 화합물을 반응시키는 단계 ; 또는 (B) 하기식(III)의 퓨린 또는 피리미딘 염기 또는 이의 기능적 등가물을 식(III)의 퓨린 또는 피리미딘 염기의 9- 또는 1- 위치에서 적합한 리보 푸라노실환을 유입하도록 돕는 화합물과 반응시킨 후나 또는 반응시킴과 동시에 후술되는 전환의 하나 또는 그 이상을 행하는 단계 : (i) 식 (I) 화합물이 생성되면 이것을 약학적 허용유도체로 전환함 ; (ii) 식 (I) 화합물의 약학적 허용 유도체가 생성되면 이 유도체를 식(I) 화합물 또는 이의 따른 유도체로 전환함 ; (iii) 식 (I) 화합물 또는 이의 약학적 허용 유도체를 R1(식A), 또는 R2또는R3(식B)기등이 다른 R1, R2또는 R3기로 치환된 식(I)의 다른 화합물 또는 이의 약학적 허용 유도체로 전환함.
    상기식 B는 제1항에서 정의한 것과 같고 Ra는 히드록시기의 또는 식(II)의 약학적 허용 유도체기의 전구체기이다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880014472A 1987-11-07 1988-11-04 약학적 뉴클레오시드 KR890008160A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB878726136A GB8726136D0 (en) 1987-11-07 1987-11-07 Therapeutic nucleosides
GB8726136 1987-11-07

Publications (1)

Publication Number Publication Date
KR890008160A true KR890008160A (ko) 1989-07-10

Family

ID=10626612

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880014472A KR890008160A (ko) 1987-11-07 1988-11-04 약학적 뉴클레오시드

Country Status (17)

Country Link
US (1) US5574149A (ko)
EP (3) EP0669341A1 (ko)
JP (1) JP2731551B2 (ko)
KR (1) KR890008160A (ko)
AT (1) ATE131826T1 (ko)
AU (1) AU616914B2 (ko)
CA (1) CA1333391C (ko)
DE (1) DE3854811T2 (ko)
DK (1) DK615788A (ko)
ES (1) ES2081286T3 (ko)
FI (1) FI91763C (ko)
GB (1) GB8726136D0 (ko)
GR (1) GR3019379T3 (ko)
HU (2) HU200931B (ko)
MX (1) MX9203217A (ko)
PT (1) PT88948B (ko)
ZA (1) ZA888289B (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506215A (en) * 1987-11-03 1996-04-09 Medivir Ab 1-(3'-fluoro-2',3'-dideoxy-β-D-ribofuranosyl)-5-substituted pyrimidine nucleosides
US5157114A (en) * 1988-08-19 1992-10-20 Burroughs Wellcome Co. 2',3'-dideoxy-3'-fluoro-5-ethyngluridine
WO1990003978A1 (en) * 1988-10-03 1990-04-19 Stichting Rega Vzw 5-halogeno-3'-fluoro-2',3'-dideoxyuridine compounds and their therapeutic application
JPH05501404A (ja) * 1989-11-06 1993-03-18 ニユコメド・アクシエセルカペト ヌクレオシド誘導体
FR2668153B1 (fr) * 1990-10-22 1995-03-31 Pasteur Merieux Serums Vacc Nouveaux composes ribonucleosides, leur procede de preparation et les medicaments les contenant.
ATE178335T1 (de) * 1992-01-06 1999-04-15 Wellcome Found Therapeutische nukleoside der 2',3'-dideoxy-3'- fluor -purin reihe
GB9200150D0 (en) * 1992-01-06 1992-02-26 Wellcome Found Therapeutic nucleosides
AU6551094A (en) * 1993-03-31 1994-10-24 Sterling Winthrop Inc. Bifunctional nucleosides, oligomers thereof, and methods of making and using the same
AU6686394A (en) * 1993-05-12 1994-12-12 Rhone-Poulenc Chemicals Limited Preparation of fluoro-nucleosides and intermediates for use therein
ATE220558T1 (de) * 1997-11-22 2002-08-15 Roche Diagnostics Gmbh Verbessertes verfahren zur stabilisierung von proteinen
US6156349A (en) * 1998-12-14 2000-12-05 Steinbach, Pylant And Herman, L.L.C. Method of treating HIV infection with suppository containing mammalian liver extract
US6514979B1 (en) 1999-03-03 2003-02-04 University Of Maryland Biotechnology Institute Synergistic combinations of guanosine analog reverse transcriptase inhibitors and inosine monophosphate dehydrogenese inhibitors and uses therefor
BR0210594A (pt) * 2001-06-22 2005-11-01 Pharmasset Ltd (beta)-d ou (beta)-l-3-halonucleosìdeo

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3328388A (en) * 1964-09-02 1967-06-27 Merck & Co Inc Arabinofuranosyl pyrimidines and methods of preparing same
US3775397A (en) * 1969-11-12 1973-11-27 Akad Wissenschaften Ddr Novel cytostatic 2',3'-dideoxy-3'-fluoropyrimidine-nucleosides
SE8602981D0 (sv) * 1986-07-04 1986-07-04 Astra Laekemedel Ab Novel medicinal use
DD279407A1 (de) * 1986-07-24 1990-06-06 Akad Wissenschaften Ddr Verfahren zur herstellung eines mittels gegen aids
US5153180A (en) * 1986-07-24 1992-10-06 Eckart Matthes Fluorinated nucleosides and process for treating retrovirus infections therewith
GB8719877D0 (en) * 1987-08-22 1987-09-30 Wellcome Found Antiviral compounds
SE8704298D0 (sv) * 1987-11-03 1987-11-03 Astra Ab Compounds for use in therapy

Also Published As

Publication number Publication date
AU2476388A (en) 1989-05-25
FI91763B (fi) 1994-04-29
ZA888289B (en) 1990-07-25
CA1333391C (en) 1994-12-06
FI885094A0 (fi) 1988-11-04
EP0670328A1 (en) 1995-09-06
HUT48466A (en) 1989-06-28
EP0317128B1 (en) 1995-12-20
EP0317128A3 (en) 1991-10-02
US5574149A (en) 1996-11-12
GB8726136D0 (en) 1987-12-09
PT88948B (pt) 1993-02-26
DE3854811T2 (de) 1996-08-01
MX9203217A (es) 1992-07-01
AU616914B2 (en) 1991-11-14
JPH01153697A (ja) 1989-06-15
GR3019379T3 (en) 1996-06-30
ATE131826T1 (de) 1996-01-15
DE3854811D1 (de) 1996-02-01
DK615788A (da) 1989-05-08
PT88948A (pt) 1988-12-01
HU204839B (en) 1992-02-28
HU200931B (en) 1990-09-28
FI91763C (fi) 1994-08-10
EP0317128A2 (en) 1989-05-24
FI885094A (fi) 1989-05-08
EP0669341A1 (en) 1995-08-30
HU902123D0 (en) 1990-07-28
JP2731551B2 (ja) 1998-03-25
ES2081286T3 (es) 1996-03-01
DK615788D0 (da) 1988-11-04

Similar Documents

Publication Publication Date Title
US4788181A (en) 5-substituted-2',3'-dideoxycytidine compounds with anti-HTLV-III activity
US3817980A (en) 5-azapyrimidine nucleosides
CA1336088C (en) 1-(3'-substitued-2', 3'-dideoxy-d-ribofuranosyl) thymine and uracil
Fox et al. Nucleosides. XXIX. 1-β-D-Arabinofuranosyl-5-fluorocytosine and Related Arabino Nucleosides1
US4880782A (en) Method of treating viral infections in humans and compositions therefor
KR890008160A (ko) 약학적 뉴클레오시드
CA1269044A (en) Inhibition of in vitro infectivity and cytopathic effect of htlv-iii/lav by 2'3'-dideoxyinosine, 2'3' - dideoxyguanosine, or 2'3' -dideoxyadenosine
EP0322384B1 (en) Nucleosides for use in therapy
KR880007521A (ko) 항비루스성 화합물
Mikhailopulo et al. Synthesis and antiviral and cytostatic properties of 3'-deoxy-3'-fluoro-and 2'-azido-3'-fluoro-2', 3'-dideoxy-D-ribofuranosides of natural heterocyclic bases
MY121839A (en) Antiviral purine derivatives
EP0355135A4 (en) ANTI-RETROVIRAL ADENOSINE NUCLEOSIDES STABLE UNDER THE INFLUENCE OF ADENOSINE DEAMINASE.
KR880012630A (ko) 치료적 뉴클레오시드
BR0011521B1 (pt) Compostos nucleósidos de purina de 4 -c-etinila
KR890008161A (ko) 2',3'-디데옥시-2'-플루오로뉴클레오사이드류
KR880012628A (ko) 치료학적인 뉴클레오시드
ES8802363A1 (es) Procedimiento para la fabricacion de derivados nucleosidos
KR870008911A (ko) 카르보사이클릭 퓨린 누클레오시드, 그의 제조방법 및 용도
Ramasamy et al. A facile synthesis of tubercidin and related 7-deazapurine nucleosides via the stereospecific sodium salt glycosylation procedure
KR910007533A (ko) 치료용 뉴클레오시드
NO932287L (no) 2'-deosky-2',2'-difluor(2,6,8-substituerte)purin-nukleosider med antiviralog anticanceraktivitet, og mellomprodukter
EP0286825A2 (en) Use of 3'-fluro-3' deoxythymidine for the manufacture of a medicament for the treatment of virus infections
GR3035931T3 (en) Process for the preparation of 1-(2'-deoxy-2',2'-difluoro-d-ribo-pentofuranosyl)-cytosine from 2-deoxy-2,2-difluoro-beta-d-ribo-pentopyranose
EP0330992A3 (en) Novel cyclobutane derivatives, processes for their preparation and pharmaceutical compositions comprising them
EP0340778A3 (en) Prodrugs of 2',3'- didehydro-2',3'-dideoxynucleosides

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application